HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia.

Abstract
Nine patients with nonlymphocytic leukaemia and one patient with refractory anaemia with excess of blasts (RAEB) were treated subcutaneously with Ara-C at a low dose of 10 mg/m2/12 h; complete remission was obtained in seven patients. In all cases severe pancytopenia was observed during treatment. We measured the concentration of Ara-C in serum, and found that the maximum concentration reached a peak (52-132 ng/ml; mean 84.2 ng/ml) at 15 min following injection. These concentrations can be considered sufficient to inhibit DNA synthesis. Primary short-term culture of human leukaemic cells with low dose Ara-C was also performed, and differentiation of leukaemic cells was observed for several types of leukaemic cells. The in vitro findings corresponded to the observed clinical effects. From the above results, the action of low dose Ara-C may have resulted from a combination of two different mechanisms, its cytostatic effect and its differentiation-inducing effect.
AuthorsH Ishikura, H Sawada, T Okazaki, T Mochizuki, Y Izumi, M Yamagishi, H Uchino
JournalBritish journal of haematology (Br J Haematol) Vol. 58 Issue 1 Pg. 9-18 (Sep 1984) ISSN: 0007-1048 [Print] ENGLAND
PMID6466575 (Publication Type: Journal Article)
Chemical References
  • Cytarabine
Topics
  • Adult
  • Aged
  • Anemia, Aplastic (drug therapy)
  • Cell Differentiation (drug effects)
  • Cells, Cultured
  • Cytarabine (administration & dosage, blood, pharmacology, therapeutic use)
  • Female
  • Humans
  • Leukemia (blood, drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: